Panakeia
Panakeia
Panakeia develops biology-first AI to deliver rapid, instrument‑free multi‑omics and biomarker profiling directly from routine brightfield (H&E) tissue images. Our mission is to make precision cancer diagnostics and molecular profiling faster, cheaper and widely accessible for clinicians, hospitals, and drug developers.
What we offer
We provide the PANProfiler platform and clinical products that predict biomarker status across DNA, RNA, proteins and metabolites from standard pathology images — no additional tissue or special lab equipment required. Our solutions produce reliable results in minutes instead of days or weeks, supporting faster treatment decisions and more efficient clinical workflows.
Key capabilities and impact:
- In silico multi‑omics biomarker profiling from routine tissue images
- Clinical products (e.g. PANProfiler Colorectal and PANProfiler Breast) validated and deployed in NHS hospitals
- UKCA‑marked devices and peer‑reviewed clinical validation
- Applications across diagnostics, translational research, and drug discovery
Founded by clinicians, scientists and engineers, Panakeia partners with healthcare institutions and research organisations to scale trustworthy AI in medicine.